{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:23:38Z","timestamp":1791908618774,"version":"4.3.4"},"reference-count":200,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>Over the course of nearly six decades since the inception of initial trials involving 5-FU in the treatment of mCRC (metastatic colorectal cancer), our progressive comprehension of the pathophysiology, genetics, and surgical techniques related to mCRC has paved the way for the introduction of novel therapeutic modalities. These advancements not only have augmented the overall survival but have also positively impacted the quality of life (QoL) for affected individuals. Despite the remarkable progress made in the last two decades in the development of chemotherapy, immunotherapy, and target therapies, mCRC remains an incurable disease, with a 5-year survival rate of 14%. In this comprehensive review, our primary goal is to present an overview of mCRC treatment methods following the latest guidelines provided by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the American Society of Colon and Rectal Surgeons (ASCRS). Emphasis has been placed on outlining treatment approaches encompassing chemotherapy, immunotherapy, targeted therapy, and surgery's role in managing mCRC. Furthermore, our review delves into prospective avenues for developing new therapies, offering a glimpse into the future of alternative pathways that hold potential for advancing the field.<\/jats:p>","DOI":"10.3389\/fsurg.2024.1398289","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:44:37Z","timestamp":1718340277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Navigating through novelties concerning mCRC treatment\u2014the role of immunotherapy, chemotherapy, and targeted therapy in mCRC"],"prefix":"10.3389","volume":"11","author":[{"given":"Edward","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"W\u0119giel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Osielczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mo\u017cd\u017can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biskup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Grochowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wo\u0142yniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Porc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Mary\u0144czak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Dziki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1186\/S12885-020-07656-W","article-title":"Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis","volume":"20","author":"Rumpold","year":"2020","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/9781420016307-2","article-title":"Epidemiology of colorectal cancer","volume":"7","author":"Marley","year":"2016","journal-title":"Int J Mol Epidemiol Genet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcm7020022","article-title":"Evaluation of colorectal cancer incidence trends in the United States (2000\u20132014)","volume":"7","author":"Ansa","year":"2018","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cam4.2673","article-title":"Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3332\/ecancer.2015.520","article-title":"Biology of colorectal cancer","volume":"9","author":"Arvelo","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/J.SURONC.2010.01.001","article-title":"Rectal cancer surgery: a brief history","volume":"20","author":"Galler","year":"2011","journal-title":"Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/ijms24021702","article-title":"Current targeted therapy for metastatic colorectal cancer","volume":"24","author":"Ohishi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2174\/0929867324666170111152436","article-title":"Colorectal cancer chemotherapy: the evolution of treatment and new approaches","volume":"24","author":"McQuade","year":"2017","journal-title":"Curr Med Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4251\/wjgo.v15.i1.55","article-title":"Challenges and exploration for immunotherapies targeting cold colorectal cancer","volume":"15","author":"Li","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","article-title":"Exploring immunotherapy in colorectal cancer","volume":"15","author":"Weng","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/J.CTARC.2021.100442","article-title":"Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?","volume":"28","author":"Arrichiello","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1200\/edbk_200821","article-title":"Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management","volume":"38","author":"Overman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","first-page":"5248","article-title":"A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238\/SUPPL_FILE\/PROTOCOL_2015.634238.PDF","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"8332","DOI":"10.1158\/1078-0432.CCR-05-1030","article-title":"Microsatellite instability and colorectal cancer prognosis","volume":"11","author":"Benatti","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial","volume":"40","author":"Morano","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12885-020-07169-6","article-title":"AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer","volume":"20","author":"Antoniotti","year":"2020","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/JCA.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B26","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/FIMMU.2022.964442\/BIBTEX","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1121285","DOI":"10.3389\/fimmu.2023.1121285","article-title":"Diversity of immune checkpoints in cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.3390\/cancers14204974","article-title":"Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability","volume":"14","author":"Borelli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","article-title":"The interaction properties of costimulatory molecules revisited","volume":"17","author":"Collins","year":"2002","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","article-title":"Treg and CTLA-4: two intertwining pathways to immune tolerance","volume":"45","author":"Walker","year":"2013","journal-title":"J Autoimmun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/13543784.2019.1559297","article-title":"CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy","volume":"28","author":"Szostak","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"B35","first-page":"96","article-title":"Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase IB KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1470-2045(16)30098-510.1016\/S1470-2045(16)30221-210.1016\/S1470-2045(19)30018-X","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet OncolLancet Oncol.Lancet Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/nejmoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet OncolLancet Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"S250","DOI":"10.1016\/j.annonc.2022.04.104","article-title":"P-12 A phase 3 study of nivolumab (NIVO), NIVO+ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): checkMate 8HW","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"DrugsDrugs."},{"key":"B43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11523-021-00843-0","article-title":"Durvalumab: a review in extensive-stage SCLC","volume":"17","author":"Al-Salama","year":"2022","journal-title":"Target OncolTarget Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ijc.33966","article-title":"Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high\/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer","volume":"150","author":"Oh","year":"2022","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","article-title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","volume":"29","author":"Thibaudin","year":"2023","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-017-0749-6","article-title":"Avelumab: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet OncolLancet Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/psp4.12771","article-title":"Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma","volume":"11","author":"Masters","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/oncolo\/oyad162","article-title":"Avelumab in patients with metastatic colorectal cancer","volume":"28","author":"Redman","year":"2023","journal-title":"Oncologist"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"v123","DOI":"10.1093\/annonc\/mdy208.003","article-title":"Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer","volume":"29","author":"Bendell","year":"2018","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"v203","DOI":"10.1093\/annonc\/mdz246.011","article-title":"BACCI: a phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): an ACCRU network study","volume":"30","author":"Mettu","year":"2019","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/nejmoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"25","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40265-023-01884-7","article-title":"Retifanlimab: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1002\/cncr.32163","article-title":"Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer","volume":"125","author":"Piawah","year":"2019","journal-title":"Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clcc.2017.03.001","article-title":"HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy","volume":"16","author":"Takegawa","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/vaccines10040499","article-title":"EGFR-based targeted therapy for colorectal cancer\u2014promises and challenges","volume":"10","author":"Janani","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","article-title":"Erbb receptors and cancer","volume":"1652","author":"Wang","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1128\/mcb.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol Cell Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"B64","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2017.5245","article-title":"Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses a phase 2 randomized clinical trial","volume":"5","author":"Montagut","year":"2019","journal-title":"JAMA OncolJAMA Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI Plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br J Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic landscape and future direction of metastatic colorectal cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/nejmoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/nejmoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1200\/JCO.23.01021","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab versus cetuximab as maintenance therapy in first-line therapy for RAS and BRAF wild-type metastatic colorectal cancer: phase III ERMES study","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2022","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2012.42.2592","article-title":"Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab","volume":"30","author":"Tejpar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaoncol.2023.0655","article-title":"Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"10","author":"Napolitano","year":"2024","journal-title":"JAMA OncolJAMA Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/jco.2022.40.16_suppl.3503","article-title":"Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI\/PANI) for first-line treatment of patients (pts) with RAS\/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): the IMPROVE study","volume":"40","author":"Avallone","year":"2022","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","article-title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.clcc.2020.06.009","article-title":"Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer","volume":"19","author":"Tosi","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/cas.15660","article-title":"Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: a phase 2 trial","volume":"114","author":"Fu","year":"2023","journal-title":"Cancer Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clcc.2022.07.003","article-title":"Dual HER2 targeted therapy with pyrotinib and trastuzumab in refractory HER2 positive metastatic colorectal cancer: a result from HER2-FUSCC-G study","volume":"21","author":"Chang","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clcc.2023.10.008","article-title":"Efficacy of pyrotinib with\/without trastuzumab in treatment-refractory, HER2-positive metastatic colorectal cancer: result from a prospective observational study","volume":"23","author":"Zhou","year":"2024","journal-title":"Clin Colorectal Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"102078","DOI":"10.1016\/j.clinre.2023.102078","article-title":"Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: what should we expect from a meta-analysis?","volume":"47","author":"Wang","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1756-8722-5-63","article-title":"Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy","volume":"5","author":"Sun","year":"2012","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/sj.bjc.6603923","article-title":"Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer","volume":"97","author":"Kut","year":"2007","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"114rv3","DOI":"10.1126\/scitranslmed.3003149","article-title":"Forty-year journey of angiogenesis translational research","volume":"3","author":"Cao","year":"2011","journal-title":"Sci Transl Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/nejmoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/nejmoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI Plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet OncolLancet Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-019-03855-w","article-title":"Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer","volume":"84","author":"Suzuki","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s10147-018-01391-w","article-title":"Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer","volume":"24","author":"Yoshihiro","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2057\u201364","DOI":"10.1016\/j.jfma.2022.02.019","article-title":"Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer","volume":"121","author":"Liang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"B101","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1080\/14712598.2021.1935231","article-title":"Up-to-date role of aflibercept in the treatment of colorectal cancer","volume":"21","author":"Gonzalez","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/annonc\/mdw176","article-title":"Oxaliplatin and 5-FU\/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study","volume":"27","author":"Folprecht","year":"2016","journal-title":"Ann Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/cancers12040844","article-title":"Safety of aflibercept in metastatic colorectal cancer: a literature review and expert perspective on clinical and real-world data","volume":"12","author":"Muro","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2217\/fon-2017-0512","article-title":"Regorafenib in the treatment of metastatic colorectal cancer","volume":"14","author":"De La Fouchardi\u00e8re","year":"2018","journal-title":"Future Oncology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet OncolLancet Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"B112","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602234","article-title":"Update on sporadic colorectal cancer genetics","volume":"31","author":"Hardiman","year":"2018","journal-title":"Clin Colon Rectal Surg"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.2147\/OTT.S242224","article-title":"Recent advances in our knowledge of mCRC tumor biology and genetics: a focus on targeted therapy development","volume":"14","author":"Gmeiner","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13578-019-0361-4","article-title":"Signaling pathways involved in colorectal cancer progression","volume":"9","author":"Koveitypour","year":"2019","journal-title":"Cell Biosci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","article-title":"NTRK insights: best practices for pathologists","volume":"35","author":"Hechtman","year":"2022","journal-title":"Mod Pathol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B119","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/PAS.0000000000001377","article-title":"Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00428-023-03538-1","article-title":"Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer","volume":"482","author":"Schraa","year":"2023","journal-title":"Virchows Arch"},{"key":"B121","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cam4.4561","article-title":"NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability","volume":"11","author":"Wang","year":"2022","journal-title":"Cancer Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-018-0622-4","article-title":"Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers","volume":"11","author":"Chen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"12","author":"Jiang","year":"2022","journal-title":"Acta Pharm Sin BActa Pharm Sin B."},{"key":"B124","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/j.annonc.2022.04.430","article-title":"SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset","volume":"33","author":"Garralda","year":"2022","journal-title":"Ann Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/J.APSB.2023.11.010","article-title":"Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib","volume":"14","author":"Xiang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.21037\/atm-20-5118","article-title":"A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients","volume":"8","author":"Sun","year":"2020","journal-title":"Ann Transl Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3390\/BIOMEDICINES11102650","article-title":"Targeting FGFR pathways in gastrointestinal cancers: new frontiers of treatment","volume":"11","author":"Ratti","year":"2023","journal-title":"Biomedicines"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/cancers12082010","article-title":"Chemosensitivity of patient-derived cancer stem cells identifies colorectal cancer patients with potential benefit from FGFR inhibitor therapy","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41416-022-01878-4","article-title":"The novel FGFR inhibitor F1-7 induces DNA damage and cell death in colon cells","volume":"127","author":"Liu","year":"2022","journal-title":"Br J Cancer"},{"key":"B130","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/jco.2023.41.4_suppl.139","article-title":"A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF\/FGFR alterations","volume":"41","author":"Ciombor","year":"2023","journal-title":"J Clin Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1055-9965.EPI-15-0649","article-title":"A cross-cancer genetic association analysis of the DNA repair and DNA damage signaling pathways for lung, ovary, prostate, breast, and colorectal cancer","volume":"25","author":"Scarbrough","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B132","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (1979)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"549777","DOI":"10.3389\/fonc.2020.549777","article-title":"DNA damage repair gene mutations are indicative of a favorable prognosis in colorectal cancer treated with immune checkpoint inhibitors","volume":"10","author":"Song","year":"2021","journal-title":"Front Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12885-021-07926-1","article-title":"Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Cancer"},{"key":"B135","doi-asserted-by":"publisher","first-page":"10187","DOI":"10.1002\/cam4.5716","article-title":"Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2020.09.006","article-title":"The impact of ARID1A mutation on molecular characteristics in colorectal cancer","volume":"140","author":"Tokunaga","year":"2020","journal-title":"Eur J Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/COC.0000000000000785","article-title":"Mutations in DNA repair genes and clinical outcomes of patients with metastatic colorectal cancer receiving oxaliplatin or irinotecan-containing regimens","volume":"44","author":"Marks","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e2100267","DOI":"10.1200\/po.21.00267","article-title":"Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1093\/hmg\/ddu058","article-title":"New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis","volume":"23","author":"Valle","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B141","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"963964","DOI":"10.3389\/FGENE.2022.963964\/BIBTEX","article-title":"Distinct clinical pattern of colorectal cancer patients with POLE mutations: a retrospective study on real-world data","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Genet"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4143\/crt.2020.218","article-title":"A phase II study of avelumab monotherapy in patients with mismatch repair-deficient\/microsatellite instability-high or POLE-mutated metastatic or unresectable colorectal cancer","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"key":"B144","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2183\/pjab.98.008","article-title":"RET Receptor signaling: function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers\u2014a tumor-agnostic review of biology, diagnosis and targeted therapy activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B146","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1002\/cam4.4400","article-title":"Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer","volume":"10","author":"Yang","year":"2021","journal-title":"Cancer Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"Fda approval summary: selpercatinib for the treatment of lung and thyroid cancers with ret gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/s41388-021-02059-y","article-title":"The role of R-spondin proteins in cancer biology","volume":"40","author":"ter Steege","year":"2021","journal-title":"Oncogene"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3892\/or.2020.7561","article-title":"RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer","volume":"43","author":"Matsumoto","year":"2020","journal-title":"Oncol Rep"},{"key":"B152","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.5098","article-title":"Impact of loss-of-function mutations at the RNF43 locus on colorectal cancer development and progression","volume":"245","author":"Eto","year":"2018","journal-title":"J Pathol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1073\/pnas.1508113112","article-title":"Porcupine inhibitor suppresses paracrine wnt-driven growth of Rnf43;Znrf3-mutant neoplasia","volume":"112","author":"Koo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-21-3018","article-title":"Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer","volume":"28","author":"Seeber","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"17588359231220600","DOI":"10.1177\/17588359231220600","article-title":"Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer","volume":"16","author":"Huang","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.gendis.2023.01.013","article-title":"RSPO2 As wnt signaling enabler: important roles in cancer development and therapeutic opportunities","volume":"11","author":"Srivastava","year":"2024","journal-title":"Genes Dis"},{"key":"B157","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fimmu.2020.00176","article-title":"Adoptive cell therapy targeting neoantigens: a frontier for cancer research","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3748\/WJG.V29.I10.1569","article-title":"Systemic treatment for metastatic colorectal cancer","volume":"29","author":"Leowattana","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"215816","DOI":"10.1016\/j.canlet.2022.215816","article-title":"Colorectal cancer immunotherapy-recent progress and future directions","volume":"545","author":"Zhao","year":"2022","journal-title":"Cancer Lett"},{"key":"B160","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1173","article-title":"How T cells \u201csee\u201d antigen","volume":"6","author":"Krogsgaard","year":"2005","journal-title":"Nat Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.7150\/jca.50509","article-title":"CAR-T cells for colorectal cancer: target-selection and strategies for improved activity and safety","volume":"12","author":"Li","year":"2021","journal-title":"J Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"978195","DOI":"10.3389\/fimmu.2022.978195","article-title":"CAR T-cells for colorectal cancer immunotherapy: ready to go?","volume":"13","author":"Ghazi","year":"2022","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"101575","DOI":"10.1016\/j.tranon.2022.101575","article-title":"CD166-specific CAR-T cells potently target colorectal cancer cells","volume":"27","author":"He","year":"2023","journal-title":"Transl Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"key":"B166","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/cancers15061792","article-title":"NKG2D fine-tunes the local inflammatory response in colorectal cancer","volume":"15","author":"Curio","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B168","first-page":"945","article-title":"Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo","volume":"9","author":"Deng","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fmed.2019.00270","article-title":"Association of T stage and serum CEA levels in determining survival of rectal cancer","volume":"6","author":"Wu","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s10637-020-00955-w10.1007\/s10637-020-00967-6","article-title":"The old CEACAMs find their new role in tumor immunotherapy","volume":"38","author":"Han","year":"2020","journal-title":"Invest New DrugsInvest New Drugs."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e14530","DOI":"10.1200\/jco.2023.41.16_suppl.e14530","article-title":"\u201cArmed\u201d CEA CAR-T with a SIRP\u03b3-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer","volume":"41","author":"Zhao","year":"2023","journal-title":"J Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2023.41.16_suppl.3559","article-title":"Novel GUCY2C targeting CAR-T therapy: efficacy in advanced colorectal cancer","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/cancers15010183","article-title":"Molecular basis of HER2-targeted therapy for HER2-positive colorectal cancer","volume":"15","author":"Yoshikawa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_351354","article-title":"HER2 In colorectal cancer: the long and winding road from negative predictive factor to positive actionable target","volume":"42","author":"Ahcene Djaballah","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B176","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.3390\/curroncol30090600","article-title":"A meta-analysis to assess the efficacy of HER2-targeted treatment regimens in HER2-positive metastatic colorectal cancer (mCRC)","volume":"30","author":"Chitkara","year":"2023","journal-title":"Curr Oncol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B178","doi-asserted-by":"publisher","first-page":"CT234","DOI":"10.1158\/1538-7445.am2023-ct234","article-title":"Abstract CT234: a phase I\/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","volume":"83","author":"Dumbrava","year":"2023","journal-title":"Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1200\/jco.2023.41.16_suppl.4034","article-title":"EpCAM CAR T (IMC001) for the treatment of advanced GI cancers","volume":"41","author":"Luo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jso.24578","article-title":"Colorectal cancer\u2014global burden, trends, and geographical variations","volume":"115","author":"Douaiher","year":"2017","journal-title":"J Surg Oncol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000487274","article-title":"Systematic review and meta-analysis of liver resection for colorectal metastases in elderly patients","volume":"36","author":"van Tuil","year":"2019","journal-title":"Dig Surg"},{"key":"B182","doi-asserted-by":"publisher","first-page":"iv205","DOI":"10.1093\/annonc\/mdu333.102","article-title":"Treatment (T) of metastatic colorectal cancer (mcrc) patients (pts) \u226575 years (Y) old in clinical practice: a multicenter analysis","volume":"25","author":"Grande","year":"2014","journal-title":"Ann Oncol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B184","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jgo.2013.07.007","article-title":"How we treat metastatic colon cancer in older adults","volume":"4","author":"Sanoff","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"key":"B186","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/annonc\/mdv491","article-title":"Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)","volume":"27","author":"Aparicio","year":"2016","journal-title":"Ann Oncol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/annonc\/mdr488","article-title":"Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C","volume":"23","author":"Price","year":"2012","journal-title":"Ann Oncol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-021-00869-z","article-title":"Management of metastatic colorectal carcinoma in older adults: balancing risks and benefits of novel therapies","volume":"38","author":"Correa","year":"2021","journal-title":"Drugs Aging"},{"key":"B189","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.dld.2012.09.013","article-title":"Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients","volume":"45","author":"Aparicio","year":"2013","journal-title":"Dig Liver Dis"},{"key":"B190","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1\u2013positive advanced non\u2013small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"B191","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/bjc.2011.554","article-title":"Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer","volume":"106","author":"Jehn","year":"2012","journal-title":"Br J Cancer"},{"key":"B192","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1200\/JCO.23.00506","article-title":"Initial panitumumab plus fluorouracil, leucovorin, and oxaliplatin or plus fluorouracil and leucovorin in elderly patients with RAS and BRAF wild-type metastatic colorectal cancer: the PANDA trial by the GONO foundation","volume":"41","author":"Lonardi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B193","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12885-019-5753-7","article-title":"First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the spanish cooperative group for the treatment of digestive tumours (TTD)","volume":"19","author":"Carrato","year":"2019","journal-title":"BMC Cancer"},{"key":"B194","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.3390\/cancers15215243","article-title":"BRAF inhibitors in metastatic colorectal cancer and mechanisms of resistance: a review of the literature","volume":"15","author":"Guerrero","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B195","doi-asserted-by":"publisher","first-page":"492061","DOI":"10.1155\/2014\/492061","article-title":"Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies","volume":"2014","author":"Kawashima","year":"2014","journal-title":"Sci World J"},{"key":"B196","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00262-022-03239-9","article-title":"Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model","volume":"72","author":"Hsu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B197","doi-asserted-by":"publisher","first-page":"166880","DOI":"10.1016\/j.bbadis.2023.166880","article-title":"Small-molecule drugs of colorectal cancer: current status and future directions","volume":"1870","author":"Yang","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B198","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/nanomanufacturing3020010","article-title":"Nanoemulsion in management of colorectal cancer: challenges and future prospects","volume":"3","author":"Mohite","year":"2023","journal-title":"Nanomanufacturing"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/ijms18061310","article-title":"Microbiota, inflammation and colorectal cancer","volume":"18","author":"Lucas","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B200","doi-asserted-by":"publisher","first-page":"615056","DOI":"10.3389\/fimmu.2020.615056","article-title":"The intestinal microbiota and colorectal cancer","volume":"11","author":"Cheng","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1398289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:44:44Z","timestamp":1718340284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1398289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":200,"alternative-id":["10.3389\/fsurg.2024.1398289"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2024.1398289","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"article-number":"1398289"}}